NR4A1 and neoplasm: 2.Collection of basket trials. Patients were assigned to one of 8 subtypes defined by 3 molecular tumor markers: hormone receptor status (HR), HER2 receptor status (HER2), and MammaPrint (MP). Investigational arms were evaluated in up to 10 signatures that are combinations patient subtypes and that are possible clinical indications.